Kura Oncology, Inc.
KURA · XNASCIK 1422143fmd_07WE19YX43GJTF2D9YBHMTGS0FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 69 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 0 | 54 | 67 |
| Research and development | – | 26 | 47 | 48 | 60 | 85 | 93 | 115 | 170 | 251 |
| Selling, general and administrative | – | – | – | – | – | – | – | 51 | 77 | 120 |
| Total operating expenses | 28 | 36 | 63 | 67 | 92 | 131 | 140 | 166 | 247 | 371 |
| Operating income | – | – | – | – | – | – | (140) | (166) | (193) | (304) |
| Interest expense | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 2 | 2 |
| Interest and investment income | 0 | 1 | 3 | 5 | 3 | 1 | 4 | 15 | 23 | 27 |
| Other non-operating income (expense) | 1 | 1 | 2 | 4 | 2 | 1 | 4 | 13 | 21 | 25 |
| Income before taxes | – | – | – | – | – | – | (136) | (153) | (172) | (278) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | (136) | (153) | (174) | (279) |
| Net income | (28) | (35) | (60) | (63) | (90) | (130) | (136) | (153) | (174) | (279) |